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Close physical proximity between mast cells andT cells has been demonstrated in several
T cell mediated inﬂammatory processes such as rheumatoid arthritis and sarcoidosis. How-
ever, the way by which mast cells are activated in theseT cell-mediated immune responses
has not been fully elucidated. We have identiﬁed and characterized a novel mast cell acti-
vation pathway initiated by physical contact with activated T cells, and showed that this
pathway is associated with degranulation and cytokine release.The signaling events asso-
ciated with this pathway of mast cell activation have also been elucidated conﬁrming the
activation of the Ras mitogen-activated protein kinase systems. More recently, we hypoth-
esized and demonstrated that mast cells may also be activated by microparticles released
from activated T cells that are considered as miniature version of a cell. By extension,
microparticles might affect the activity of mast cells, which are usually not in direct contact
withT cells at the inﬂammatory site. Recent works have also focused on the effects of regu-
latoryT cells (Treg) onmast cells.These reports highlighted the importance of the cytokines
IL-2 and IL-9, produced by mast cells andT cells, respectively, in obtaining optimal immune
suppression. Finally, physical contact, associated by OX40–OX40L engagement has been
found to underlie the down-regulatory effects exerted byTreg on mast cell function.
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INTRODUCTION
Most commonly known for their role in the elicitation of IgE-
mediated allergic inﬂammation, mast cells have been implicated
in a range of other non-allergic inﬂammatory processes. Obser-
vations such as the close physical proximity between mast cells
and T cells in inﬂamed tissues and the capability of the for-
mer to release a wide range of immunomodulatory mediators
and to express surface molecules important in costimulation in
both adaptive and innate immunity, have led investigators to pro-
pose a functional bi-directional relationship between these two
cell populations (Mekori, 2004; Bachelet et al., 2006; Kalesnikoff
and Galli, 2008). Indeed, morphologic studies have documented
an increase in the local density of mast cells and their activa-
tion during T cell-mediated inﬂammatory processes, as observed
in cutaneous delayed-type hypersensitivity, graft-versus-host reac-
tions, sarcoidosis, Crohn’s disease, rheumatoid arthritis, and ﬁbro-
sis (Mekori, 2004; Bachelet et al., 2006; Kalesnikoff andGalli, 2008;
Dudeck et al., 2011). Both in vitro and in vivo studies have demon-
strated that mast cells or their products are pivotal in mediating
leukocyte recruitment into inﬂammatory sites, are capable of pre-
senting antigens to T cells, interact directly with and affect the
function of cells of the adaptive immune system, and mediate tis-
sue remodeling (Mekori, 2004; Bachelet et al., 2006; Kalesnikoff
and Galli, 2008; Dudeck et al., 2011). For instance, by usingW/W v
mice reconstituted with mast cells obtained from TNF−/− mice, it
could be shown in vivo that TNF-α and MIP-2 (the functional
murine analog of human IL-8) were essential for appropriate
neutrophil recruitment during T cell-induced cutaneous delayed
hypersensitivity reactions. Both cytokines were dependent on the
presence of mast cells (Biedermann et al., 2000). The combina-
tion of these two mediators is crucial for cell recruitment because
TNF-α and MIP-2 provide two qualitatively different but syner-
gistic signals. The induction of MIP-2 and TNF-α were strictly
dependent on the presence of mast cells and local activation of
memory T cells, indicating that the inﬁltrating T cells deliver sig-
nals that induced both TNF-α andMIP-2 production bymast cells
(Biedermann et al., 2000). However, the way by which T cells acti-
vate mast cells in T cell-mediated immune responses have not yet
been fully elucidated.
The understanding of T cell–mast cell interactions is further
complicated by the fact that these two cell types have been shown to
be both pro- and anti-inﬂammatory, depending on the immuno-
logical setting. In the case of T cells, it is well established that
both effector and regulatory types exist (Shevach, 2006). Since the
mid 1990s, a subset of CD4+CD25+ cells have been rigorously
characterized as pivotal players in dampening immune responses
(Shevach, 2004). This regulatory role is dependent on the expres-
sion of the transcription factor Foxp3. Likewise, there is strong
evidence that mast cells, traditionally recognized as enhancers of
inﬂammation, can also suppress certain disease models, thus sug-
gesting the concept of “regulatory mast cells” (Frossi et al., 2010).
However, contrary to regulatory T cells (Treg), the phenotypic
www.frontiersin.org January 2012 | Volume 3 | Article 6 | 1
Mekori and Hershko T cells modulate mast cell function
features, and mode of action are considerably less understood in
suppressor mast cells. Recent studies on T cell effects on mast cell
function in the regulatory context are discussed in the present
communication.
MAST CELL ACTIVATION BY HETEROTYPIC ADHESION TO T
CELLS
We have previously reported on the effects of direct contact
between mast cells and T lymphocytes on mast cell activation
and mediator release. Both murine and human mast cells could
be activated to both release granule-associated mediators, such as
histamine and matrix metalloproteinase-9 (MMP-9), and to pro-
duce several cytokines (i.e., TNF-α, IL-4, IL-6, and IL-8) upon
physical contact with activated, but not resting, T cells (Inamura
et al., 1998; Baram et al., 2001; Salamon et al., 2005, 2008). Fur-
thermore, the expression and release of these mediators, were also
induced when mast cells were incubated with cell membranes iso-
lated from activated, but not resting, T cells (Baram et al., 2001;
Salamon et al., 2005, 2008). Gene expression proﬁling validated
by qRT-PCR has demonstrated the expression and production of
cytokines (oncostatinM) and enzymes (MMP-9) that were specif-
ically induced by this novel here-to-fore unknown pathway of
activation (Salamon et al., 2008). Studies with murine mast cells
and myristate 13-acetate (PMA) – or anti-CD3-activated T cells
attributed the T cell-induced mast cell activation to interactions
of surface molecules, such as intercellular adhesion molecule 1
and lymphotoxin-β receptor, with their respective ligands (Baram
et al., 2001; Stopfer et al., 2004). Thus, direct contact between
surface molecules on mast cells and on activated T cells was
found to provide the stimulatory signal in mast cells necessary
for degranulation and cytokine release independent of T cell
intracellular function, and in the absence of demonstrable sol-
uble mediators. Indeed, separation of the two cell populations
by a semipermeable porous membrane prevented this pathway
of mast cell activation (Bhattacharyya et al., 1998; Baram et al.,
2001).
The kinetics of the heterotypic adhesion-inducedmast cell acti-
vation was found to be slow in nature. For example, MMP-9
release, found to be granule-associated, was ﬁrst detected at 6 h
and peaked at 22 h of incubation with activated T cell membranes,
while TNF-α release peaked after only 6 h.Anti-TNF-αmAb inhib-
ited the T cell membrane-inducedMMP-9 expression and release,
indicating a possible autocrine regulation of MMP release by mast
cell TNF-α (Baram et al., 2001; Figure 1).When analyzing the sig-
naling events that are associated with this novel pathway of mast
cell activation we found that it is associated with phosphorylation
FIGURE 1 | Heterotypic adhesion-induced mast cell activation. Mast cells
can be activated by physical contact with activated, but not resting, T cells
and/or by microvesicles released from the latter. This contact involves
adhesion molecules such as integrins, lymphotoxin β receptor, and other yet
unspeciﬁed surface molecules. Contact with membranes, derived from
activatedT cells, stimulate ERK1/2 activation, causing the expression of
cytokines, chemokines, and growth factors. On contact with T cell
membranes, adenosine is formed and released. By binding to its speciﬁc A3
receptors, adenosine initiates a complex signaling cross-talk, whereby the
A3R, by coupling to the G-protein Gi3, eventually contributes to ERK1/2
signaling. N-Ras but not K Ras may be involved in this pathway or be directly
activated by a yet undisclosed pathway and results in sustained ERK
activation that is associated with increased dwell time at the nucleus and with
cytokine release. Adhesion to activatedT cells also results in an early
(preformed) TNF-α release that affects in an autocrine manner the expression
and production of the granule-associated enzyme MMP-9.
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FIGURE 2 | Proposed paradigms ofTreg–mast cell (MC) interaction.
Several modes of interaction have been described for Treg effects on MC
activation and for the cross-talk between the two cells (from top left
clockwise): Failure of Treg-mediated IgE suppression enhances MC
migration and IL-2 production in the spleen which, in turn, boosts Treg
activity; Treg–IL-9 production recruits MC to skin allografts where the two
cells collaborate to create tolerance; engagement of OX40L and OX40
results in inhibition of MC degranulation and dampening of anaphylaxis.
of the mitogen-activated protein kinases (MAPKs) extracellular
signal-regulated kinase (ERK) and p38 (Brill et al., 2004; Sheﬂer
et al., 2008). In this context, it has been found that cytokines such
as IL-8 and oncostatin M are released from humanmast cells after
contact with activated T cells and that this process is subject to
MAPK inhibition (Salamon et al., 2008). The best characterized
upstream regulator of the MAPK system is the small guanosine
triphosphate (GTP)-binding protein Ras. This protein has critical
functions in many cell types, however, in mast cells its functions
are not entirely understood. By investigating the spatiotemporal
pattern of Ras activation inmast cells stimulated by activated T cell
membranes, we could demonstrate that this stimulation resulted
inN-Ras activation through the activationof the guanine exchange
factor RasGRP-1 (Sheﬂer et al., 2008).
We further explored the downstream events associatedwith Ras
activation. Thus, ERK activation in human mast cells activated by
either contact with T cells or by FcεRI crosslinking was studied.
Stimulation of human mast cells by contact with activated T cells
resulted in sustained ERK activation. Furthermore, sustained ERK
activation in these cells was associated with increased dwell time
at the nucleus and with IL-8 release. Interestingly, when mast cells
were stimulated by FcεRI crosslinking, ERK activation was tran-
sient. ERKactivationwas associatedwith a shorter dwell time at the
nucleus and with TNF-α release (Mor et al., 2010). Thus, retaining
ERK in the nucleus may be a mechanism utilized by human mast
cells to generate different cytokines froma single signaling cascade.
When analyzing upstream signaling events, it has been shown that
contact with activated T cell membranes results in increased lev-
els of endogenous adenosine that binds to and activates the A3R,
culminating in Gi3-mediated signaling. Speciﬁcally, the major-
ity of ERK1/2 signaling initiated by contact with activated T cell
membranes was found to be mediated by Gi3 (Baram et al., 2010;
Figure 1).
The biological relevance of this here-to-fore unrecognized
pathway of mast cell activation can be envisaged from our ﬁnd-
ings with oncostatin M, a known ﬁbrogenic cytokine, where we
demonstrated that both oncostatin M mRNA and protein are
induced in human mast cells speciﬁcally by means of heterotypic
adhesion to activated T cells. Mast cell-derived oncostatin was
found to induce the proliferation of lung ﬁbroblasts and its pres-
ence was demonstrated in mast cells in the lungs of patients with
sarcoidosis, a disease known to culminate in ﬁbrosis (Salamon
et al., 2008). These results suggest that human mast cells might
contribute to T cell-mediated ﬁbrotic inﬂammatory processes by
means of local release of oncostatin M after direct activation by
T cells. Contact-dependent bi-directional interactions have also
been demonstrated between CD8+ T cells and mast cells, wherein
mast cells supported T cell effector functions and survival, while T
cells induced expression of co-stimulatorymolecules and cytokine
release by mast cells (Stelekati et al., 2009).
MAST CELL ACTIVATION BY T CELL-DERIVED
MICROVESICLES
Based on the above information, and due to the fact that mast
cells usually do not reside in direct contact with T cells at the
inﬂammatory sites, we further hypothesized that mast cells may
be activated not only by heterotypic adhesion to T cells, but also by
other components that may reside in the supernatants of activated
T cells and are of high molecular weight that does not allow their
migration through the porousmembranes. Possible candidates are
membrane vesicles that are secreted by T cells (Al-Nedawwi et al.,
2009; Thery et al., 2009). Many reports have described how por-
tions of cell membranes can be transferred between cells, either
after direct cell–cell contact or through the secretion of mem-
brane vesicles. The functional consequences of such membrane
transfers include the induction, ampliﬁcation, and/or modulation
of immune responses, as well as the acquisition of new functional
properties by recipient cells (Al-Nedawwi et al., 2009; Thery et al.,
2009). Cells can generate membrane vesicles that are secreted into
the extracellular space; such vesicles can form either at the plasma
membrane or in the lumen of internal compartments. Irrespec-
tive of their origin, these vesicles contain cytosol and expose the
extracellular side of the membrane they form from at their outer
surface. Because their membrane orientation is the same as that of
the donor cell, they can be considered to be miniature versions of
a cell (Thery et al., 2009). Thus, membrane transfer is a mode of
intercellular communication that may also involve T cell-induced
mast cell activation within inﬂammatory sites in which both cell
populations have been shown to be involved, such as rheumatoid
arthritis, Crohn’s disease, and sarcoidosis (Sheﬂer et al., 2011).
Consequently, we were able to show that high molecular
weight fractions (MW> 100000Da) of supernatants obtained
from T cells, that were activated by either short incubation with
PMA or with anti-CD3 anti-CD28 mAb-coated beads, contained
microvesicles (100–800 nm in diameter) that expressed the adhe-
sion molecule LFA-1/CD11a and bound Annexin V-FITC indicat-
ing that phosphatidylserine was exposed at their surface. Isolated
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microvesicles induceddegranulation and cytokine (IL-8 andonco-
statin M) release from human mast cells (Sheﬂer et al., 2010). The
results, including kinetics of the microvesicle-induced mediator
release, were similar when mast cells were stimulated by activated
ﬁxed T cells or by whole membranes of the latter. This suggests
that microvesicles carry similar mast cell-activating factors to cells
fromwhich they originate. Thus, by releasingmicrovesicles, T cells
might convey surface molecules similar to those involved in the
activation of mast cells by cellular contact. Consequently, through
the generation of microvesicles, activated T cells may facilitate dis-
tant contact-mediated activation of mast cells which are not in
direct contact with T cells at the inﬂammatory sites (Sheﬂer et al.,
2011). Blocking the release of microparticles and their interac-
tion with mast cells, as well as downstream activation events, may
serve as a therapeutic approach for T cell-mediated inﬂammatory
processes in which mast cells are involved.
REGULATORY T CELL EFFECT ON MAST CELL FUNCTION
The activation of mast cells by T cells, as described herein, can
be regarded as a mechanism underlying the propagation of T
cell-mediated inﬂammatory processes. However, one should bear
in mind that a signiﬁcant proportion of T cells specialize in
regulation and suppression of the inﬂammatory process. This
sub-population, known as Treg, may appear in several forms,
mostly characterized by the expression CD4, CD25, and the tran-
scription factor Foxp3 (Kayshap et al., 2008). Naturally occurring
Treg may account for as much as 10% of total CD4+ T cells in
mice. They have been described as pivotal players in suppressing
autoimmunity (Shevach, 2006), allergic responses, and inﬂam-
matory responses to tumors, in various systems. An intriguing
question that has been investigated in recent years is whether these
T cells can also interact with mast cells, in order to further support
suppression (Hershko and Rivera, 2010).
In a mouse model of chronic allergic dermatitis, Treg were
shown to require mast cell recruitment in order to obtain opti-
mal suppression of inﬂammation (Hershko et al., 2011). In this
model, mast cells migrated from the site of inﬂammation (skin)
to the spleen, where they secrete IL-2, a critical cytokine for Treg
proliferation and function (Figure 2). Following this process, dis-
ease was more effectively suppressed and the proportion of Treg
in the skin increased. Mast cell accumulation in the spleen was
shown to be IgE dependent. Furthermore, inhibition of Treg activ-
ity by anti-CD25monoclonal antibodies enhanced IgE production
thereby facilitating mast cell numbers in the spleen. Interestingly,
mast cell accumulation was independent of the high-afﬁnity IgE
receptor (FcεRI). However, it was abrogated following blockade
of the low afﬁnity IgE receptor, CD23, which is not expressed on
mast cells, thereby implying the involvement of another cell-type,
as mediators of mast cell recruitment.
The collaboration between Treg and mast cells in suppressing
inﬂammatory responses has been suggested by other reports as
well. The study of several disease models revealed that Treg can
attract mast cells by producing considerable amounts of IL-9, a
mast cell growth, and activation factor. This paradigm was ﬁrst
presented in a study of a skin allograft model, whose tolerance
depended on Treg activity (Lu et al., 2006). However, Treg were
not sufﬁcient to prevent rejection, and required recruitment of
mast cells to the graft. The functional link between the two cell
types was shown to be Treg-derived IL-9. Neutralization of this
cytokine by monoclonal antibodies abrogated mast cell recruit-
ment and inhibited tolerance. The role of Treg-derived IL-9 in
mast cell recruitment and disease suppression has been conﬁrmed
in subsequent reports. For example, in amurinemodel of nephro-
toxic serumnephritis (NTS),Treg were shown to effectively inhibit
disease development, and this protective effect was profoundly
compromised in mast cell-deﬁcient mice (Eller et al., 2011). Fur-
thermore, both blocking of IL-9 by monoclonal antibodies and
adoptive transfer of IL-9 deﬁcient Treg resulted in failure of mast
cell accumulation and impaired protection. The Treg, IL-9, and
mast cell connection was similarly implicated in immune suppres-
sion in B-cell non-Hodgkin’s lymphoma in human patients (Feng
et al., 2011) as well as in murine lymphoma. It is not entirely
clear, however, from these reports what is the mechanism under-
lying the contribution of IL-9 mediated mast cell recruitment to
immune suppression. This issue was more recently addressed in a
study on a murine hepatocarcinoma model (Yang et al., 2010). In
this work, mast cells were shown to support the mobilization and
inﬁltration of myeloid-derived suppressor cells (MDSCs) to the
tumor and to induce production of IL-17 by these cells. MDSC’s,
in turn, attracted Treg and stimulated them to produce IL-9,which
supportedmast cell survival and pro-tumor effect. Therefore, sim-
ilar to our work on the immunosuppressive effect of mast cells in
chronic dermatitis, it has been suggested that mast cells play a role
in promoting Treg recruitment in the hepatocellular model.
The effects that Treg exert on mast cells, however, appear
to be more complex than collaboration in suppressing immune
responses. In a model of intestinal polyposis mast cells play a
critical role in disease progression. Adoptively transferred Treg
suppressed focal mastocytosis in vivo, and thus inhibited disease
(Gounaris et al., 2009). Nevertheless, endogenous Foxp3+ Treg
populating thepolyps couldnot counteractmastocytosis andpoly-
posis. Endogenous Treg displayed defective IL-10 secretion as well
as IL-17 production andwere implicated in tumor growth through
enhancement of a mast cell-mediated inﬂammation.
The paradigm of mast cells as targets of Treg-mediated sup-
pression has been rigorously investigated in the setting of imme-
diate hypersensitivity-allergic responses. The study of this aspect
of Treg–mast cell interaction has yielded interesting mechanisti-
cal data. Mast cells were shown in vitro to have the capacity to
recruit both regulatory and conventional T cells (Kayshap et al.,
2008). This processes led to Treg-mediated inhibition of FcεRI
expression on mast cells, requiring contact between the two cell
types. However, the effects on mast cell-production of inﬂamma-
tory mediators were somewhat more complex. Both regulatory
and conventional T cell suppressed leukotriene C4 production
and enhanced cytokine secretion, along with FcεRI-induced Stat5
phosphorylation. Along this line Treg were also found to directly
inhibit the FcεRI-dependent degranulation of mast cells (Gri
et al., 2008). This effect was achieved by Treg–mast cell con-
tact leading to OX40–OX40L engagement, respectively (Figure 2).
Suppression was associated with increased cAMP and decreased
Ca2+ inﬂux, unrelated to PLC-γ2 or intracellular Ca2+ stores.
Furthermore, abrogation of cAMP increase essentially reversed
the impact of Treg on mast cells. The physiological outcome of
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mast cell suppression was conﬁrmed in vivo by the observation
that interference with Treg function resulted in exacerbation of
anaphylaxis. An elegant mechanistical insight was provided in
a subsequent work, in which time-lapse video microscopy and
transmission electron microscopy were used to record interac-
tions on a single-cell level (Frossi et al., 2011). Co-cultures of mast
cells with wild type, but not OX40-deﬁcient, Treg resulted in mor-
phological changes that indicated defective exocytosis, along with
inhibition of degranulation and of Ca2+ mobilization. Thus, an
“Immunological synapse”between the two cell types was convinc-
ingly visualized. Intriguingly, these observations have led to the
ﬁnding that soluble OX40 is sufﬁcient to mimic the inhibitory
effects of Treg (Sibilano et al., 2011), providing a potentially novel
therapeutic approach in allergic diseases.
In summary, we would like to suggest that mast cells can be
utilized by T cells in order to enhance the physiological effects
of the latter. Although T cells demonstrate considerable mast cell-
independent activity, it seems thatmast cells are required to obtain
an optimal response. This conclusion is based on data provided
by studies on both effector and Treg. Nevertheless, it should be
noted, that the role of these cell types may be contradictory, thus
leading to effects such as T (regulatory) cell counteracting mast
cell function.
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